BCOP Exam Questions with Correct Answers| Latest Update

BCOP Exam Questions with Correct Answers|
Latest Update


melanoma - Stage I or II
surgery


melanoma - Stage III
nivolumab, ipilumumab


melanoma - BRAF positive Stage III
dabrafenib + trametinib


melanoma - BRAF positive Stage IV, aggressive, bulky, symptomatic
dabrafenib + trametinib, vemurafenib + cobimetinib


melanoma - Unresectable stage III with in-transit lesions
Talimogene Laherparepvec (T-VEC)


melanoma - Stage IV
nivolumab, pembrolizumab


melanoma - BRAF positive Stage IV minimally symptomatic
nivolumab, pembrolizumab, nivolumab + ipilimumab (Stage IV immunotherapy)

,metastatic basal cell carcinoma
vismodegib, sonidegib




CLL - Age < 65 without significant comorbidies without del 17p/TP53
FCR, ibrutinib, bendamustine with or without cd20 MoAb


CLL - Age < 65 without significant comorbidities without del 17p/TP53
relapse/refractory
ibrutinib, idelalisib + R, venetoclax with or without R


CLL - Age < 65 without significant comorbidies without del 17p/TP53
maintenance
consider lenalidomide for high risk


CLL - Age > 65 or younger patients with significant comorbidities without del
17p/TP53
Obinutuzumab + chlorambucil, ibrutinib, ofatumumab + chlorambucil, rituxan +
chlorambucil, bendamustine with or without R


CLL - Age > 65 or younger patients with significant comorbidities without del
17p/TP53 maintenance
consider lenalidomide for high risk

,CLL - Age > 65 or younger patients with significant comorbidities without del
17p/TP53 relapse/refractory
ibrutinib, idelalisib + R, venetoclax with or without R




CLL - Frail patients with significant comorbidities without del 17p/TP53
Obinutuzumab + chlorambucil, ibrutinib, ofatumumab + chlorambucil, rituxan +
chlorambucil


CLL - Frail patients with significant comorbidities without del 17p/TP53
maintenance
consider lenalidomide for high risk


Frail patients with significant comorbidities without del 17p/TP53
relapsed/refractory
ibrutinib, idelalisib + R, venetoclax with or without R


CLL - With del 17p/TP53
ibrutinib**, HDMP + rituxan, obinutuzumab, alemtuzumab with or without
rituxan


CLL - With del 17p/TP53 relapsed/refractory
ibrutinib, idelalisib + R, venetoclax with or without R


CLL - With del 17p/TP53 maintenance

, consider lenalidomide for high risk




NSCLC stage IA
surgery




NSCLC stage IB
surgery




NSCLC stage IIA
surgery followed by cisplatin doublet




NSCLC stage IIB
surgery followed by cisplatin doublet




NSCLC stage IIIA
surgery followed by cisplatin doublet